Literature DB >> 27471650

IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.

Zhi-Chun Ding1, Chufeng Liu2, Yang Cao3, Tsadik Habtetsion1, Michal Kuczma1, Wenhu Pi4, Heng Kong5, Ercan Cacan6, Susanna F Greer6, Yan Cui1, Bruce R Blazar7, David H Munn1, Gang Zhou1.   

Abstract

The functional status of CD4(+) T cells is a critical determinant of antitumor immunity. Polyfunctional CD4(+) T cells possess the ability to concomitantly produce multiple Th1-type cytokines, exhibiting a functional attribute desirable for cancer immunotherapy. However, the mechanisms by which these cells are induced are neither defined nor it is clear if these cells can be used therapeutically to treat cancer. Here, we report that CD4(+) T cells exposed to exogenous IL-7 during antigenic stimulation can acquire a polyfunctional phenotype, characterized by their ability to simultaneously express IFNγ, IL-2, TNFα and granzyme B. This IL-7-driven polyfunctional phenotype was associated with increased histone acetylation in the promoters of the effector genes, indicative of increased chromatin accessibility. Moreover, forced expression of a constitutively active (CA) form of STAT5 recapitulated IL-7 in inducing CD4(+) T-cell polyfunctionality. Conversely, the expression of a dominant negative (DN) form of STAT5 abolished the ability of IL-7 to induce polyfunctional CD4(+) T cells. These in-vitro-generated polyfunctional CD4(+) T cells can traffic to tumor and expand intratumorally in response to immunization. Importantly, adoptive transfer of polyfunctional CD4(+) T cells following lymphodepletive chemotherapy was able to eradicate large established tumors. This beneficial outcome was associated with the occurrence of antigen epitope spreading, activation of the endogenous CD8(+) T cells and persistence of donor CD4(+) T cells exhibiting memory stem cell attributes. These findings indicate that IL-7 signaling can impart polyfunctionality and stemness potential to CD4(+) T cells, revealing a previously unknown property of IL-7 that can be exploited in adoptive T-cell immunotherapy.

Entities:  

Keywords:  Adoptive cell therapy; CD4+; IL-7; T memory stem cell; polyfunctional

Year:  2016        PMID: 27471650      PMCID: PMC4938319          DOI: 10.1080/2162402X.2016.1171445

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  59 in total

Review 1.  The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance.

Authors:  Terry J Fry; Crystal L Mackall
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

Review 2.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

3.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.

Authors:  Patricia A Darrah; Dipti T Patel; Paula M De Luca; Ross W B Lindsay; Dylan F Davey; Barbara J Flynn; Søren T Hoff; Peter Andersen; Steven G Reed; Sheldon L Morris; Mario Roederer; Robert A Seder
Journal:  Nat Med       Date:  2007-06-10       Impact factor: 53.440

4.  CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Authors:  Harry Z Qui; Adam T Hagymasi; Suman Bandyopadhyay; Marie-Clare St Rose; Raghunath Ramanarasimhaiah; Antoine Ménoret; Robert S Mittler; Scott M Gordon; Steven L Reiner; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2011-08-31       Impact factor: 5.422

5.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

6.  Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.

Authors:  Sergio A Quezada; Tyler R Simpson; Karl S Peggs; Taha Merghoub; Jelena Vider; Xiaozhou Fan; Ronald Blasberg; Hideo Yagita; Pawel Muranski; Paul A Antony; Nicholas P Restifo; James P Allison
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

Review 7.  Twelve immunotherapy drugs that could cure cancers.

Authors:  Martin A Cheever
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

8.  Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.

Authors:  Andrea Schietinger; Mary Philip; Rebecca B Liu; Karin Schreiber; Hans Schreiber
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

9.  Interleukin 7 induces CD4+ T cell-dependent tumor rejection.

Authors:  H Hock; M Dorsch; T Diamantstein; T Blankenstein
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.

Authors:  Claude Sportès; Frances T Hakim; Sarfraz A Memon; Hua Zhang; Kevin S Chua; Margaret R Brown; Thomas A Fleisher; Michael C Krumlauf; Rebecca R Babb; Catherine K Chow; Terry J Fry; Julie Engels; Renaud Buffet; Michel Morre; Robert J Amato; David J Venzon; Robert Korngold; Andrew Pecora; Ronald E Gress; Crystal L Mackall
Journal:  J Exp Med       Date:  2008-06-23       Impact factor: 14.307

View more
  11 in total

1.  Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death.

Authors:  Tsadik Habtetsion; Zhi-Chun Ding; Wenhu Pi; Tao Li; Chunwan Lu; Tingting Chen; Caixia Xi; Helena Spartz; Kebin Liu; Zhonglin Hao; Nahid Mivechi; Yuqing Huo; Bruce R Blazar; David H Munn; Gang Zhou
Journal:  Cell Metab       Date:  2018-06-07       Impact factor: 27.287

Review 2.  T memory stem cells in health and disease.

Authors:  Luca Gattinoni; Daniel E Speiser; Mathias Lichterfeld; Chiara Bonini
Journal:  Nat Med       Date:  2017-01-06       Impact factor: 53.440

3.  Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells.

Authors:  Zhi-Chun Ding; Tsadik Habtetsion; Yang Cao; Tao Li; Chufeng Liu; Michal Kuczma; Tingting Chen; Zhonglin Hao; Locke Bryan; David H Munn; Gang Zhou
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

4.  Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients.

Authors:  Lena Peter; Désirée Jacqueline Wendering; Stephan Schlickeiser; Henrike Hoffmann; Rebecca Noster; Dimitrios Laurin Wagner; Ghazaleh Zarrinrad; Sandra Münch; Samira Picht; Sarah Schulenberg; Hanieh Moradian; Mir-Farzin Mashreghi; Oliver Klein; Manfred Gossen; Toralf Roch; Nina Babel; Petra Reinke; Hans-Dieter Volk; Leila Amini; Michael Schmueck-Henneresse
Journal:  Mol Ther Methods Clin Dev       Date:  2022-02-26       Impact factor: 6.698

5.  IL-7-Treated Periodontal Ligament Cells Regulate Local Immune Homeostasis by Modulating Treg/Th17 Cell Polarization.

Authors:  Xin-Yi Yu; Zhao-Qiang Zhang; Jia-Chang Huang; Jia-Yu Lin; Xue-Pei Cai; Chu-Feng Liu
Journal:  Front Med (Lausanne)       Date:  2022-02-23

6.  Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy.

Authors:  Nada S Aboelella; Caitlin Brandle; Ogacheko Okoko; Md Yeashin Gazi; Zhi-Chun Ding; Hongyan Xu; Gregory Gorman; Roni Bollag; Marco L Davila; Locke J Bryan; David H Munn; Gary A Piazza; Gang Zhou
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

7.  Persistent STAT5 activation reprograms the epigenetic landscape in CD4+ T cells to drive polyfunctionality and antitumor immunity.

Authors:  Zhi-Chun Ding; Huidong Shi; Nada S Aboelella; Kateryna Fesenkova; Eun-Jeong Park; Zhuoqi Liu; Lirong Pei; Jiaqi Li; Richard A McIndoe; Hongyan Xu; Gary A Piazza; Bruce R Blazar; David H Munn; Gang Zhou
Journal:  Sci Immunol       Date:  2020-10-30

8.  The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells.

Authors:  Michal P Kuczma; Zhi-Chun Ding; Tao Li; Tsadik Habtetsion; Tingting Chen; Zhonglin Hao; Locke Bryan; Nagendra Singh; James N Kochenderfer; Gang Zhou
Journal:  Oncotarget       Date:  2017-12-05

9.  Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis.

Authors:  Liu Zhenjiang; Martin Rao; Xiaohua Luo; Elisabeth Sandberg; Jiri Bartek; Esther Schoutrop; Anna von Landenberg; Qingda Meng; Davide Valentini; Thomas Poiret; Georges Sinclair; Inti-Harvey Peredo; Ernest Dodoo; Markus Maeurer
Journal:  EBioMedicine       Date:  2017-08-30       Impact factor: 8.143

10.  Transcriptional Profiling of CD8+ CMV-Specific T Cell Functional Subsets Obtained Using a Modified Method for Isolating High-Quality RNA From Fixed and Permeabilized Cells.

Authors:  Zachary R Healy; Kent J Weinhold; David M Murdoch
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.